EP Patent

EP4509529A1 — Antibody used to treat coronavirus infection

Assigned to Shiga University of Medical Science NUC · Expires 2025-02-19 · 1y expired

What this patent protects

The present invention provides an antibody that binds to an extracellular domain of TMPRSS2, capable of inhibiting beta coronavirus infection of cells, or an antigen-binding fragment thereof, and a composition including the antibody or an antigen-binding fragment thereof.

USPTO Abstract

The present invention provides an antibody that binds to an extracellular domain of TMPRSS2, capable of inhibiting beta coronavirus infection of cells, or an antigen-binding fragment thereof, and a composition including the antibody or an antigen-binding fragment thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP4509529A1
Jurisdiction
EP
Classification
—
Expires
2025-02-19
Drug substance claim
No
Drug product claim
No
Assignee
Shiga University of Medical Science NUC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.